A61K 39/3955
Against proteinaceous materials
Official title: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
A61K39/3955 (Against proteinaceous materials) appears on 6,324 US grants and 12,898 published applications in this corpus.
Search patents in A61K- Granted patents
- 6,324
- Published applications
- 12,898
- Assignees
- 3,127
- Inventors
- 17,741
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1995 | 2 | 0 |
| 1996 | 2 | 0 |
| 1997 | 2 | 0 |
| 1998 | 7 | 0 |
| 1999 | 4 | 0 |
| 2000 | 7 | 0 |
| 2001 | 6 | 3 |
| 2002 | 10 | 27 |
| 2003 | 8 | 52 |
| 2004 | 11 | 54 |
| 2005 | 9 | 67 |
| 2006 | 22 | 90 |
| 2007 | 35 | 96 |
| 2008 | 32 | 142 |
| 2009 | 48 | 202 |
| 2010 | 70 | 268 |
| 2011 | 97 | 307 |
| 2012 | 139 | 352 |
| 2013 | 242 | 692 |
| 2014 | 315 | 805 |
| 2015 | 405 | 743 |
| 2016 | 459 | 809 |
| 2017 | 489 | 792 |
| 2018 | 438 | 813 |
| 2019 | 506 | 846 |
| 2020 | 500 | 937 |
| 2021 | 466 | 1008 |
| 2022 | 478 | 999 |
| 2023 | 386 | 887 |
| 2024 | 405 | 805 |
| 2025 | 440 | 594 |
| 2026 | 284 | 508 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Anti-Claudin18.2 antigen-binding fragment or antibody, and use thereof182551196 Oct 2026US 12,751,972 B2Guangzhou Bio-Gene Technology Co., Ltd
- Compositions and methods of treating lupus nephritis6 Oct 2026US 12,752,005 B2Genentech, Inc.
- Antibodies binding to alpha-synuclein for therapy and diagnosis6 Oct 2026US 12,753,223 B2AC Immune SA
- Camptothecin derivatives29 Sep 2026US 12,747,250 B2ImmunoGen, Inc.
- Nucleic acids encoding humanized anti-PACAP antibodies29 Sep 2026US 12,747,291 B2H. Lundbeck A.S.
- Compositions and methods for treating cancer by targeting bach18 Oct 2026US 2026/0306455 A1
- Composition for removing and inhibiting senescent cells, and uses thereof8 Oct 2026US 2026/0306460 A1Lifeceutix Co., Ltd.
- Pharmaceutical combination for cancer treatment8 Oct 2026US 2026/0306466 A1Miyarisan Pharmaceutical Co., Ltd.
- Inhaled statins as bronchodilators to improve lung function in respiratory diseases8 Oct 2026US 2026/0306477 A1Beth Israel Deaconess Medical Center, Inc.
- Inverse agonists of rar related orphan receptors (rors)8 Oct 2026US 2026/0306484 A111949098 CANADA INC. (NUREDCO) c/o Jean I. TCHERVENKOV
Most cited
By later US patents
- Interleukin-1α antibodies1,029US 8,034,337 B2Xbiotech, Inc. · 2011
- Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics940US 8,008,449 B2Medarex, Inc. · 2011
- Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation733US 9,101,621 B2Celgene Corporation · 2015
- Anti-PD-L1 antibodies, compositions and articles of manufacture459US 8,217,149 B2Genentech, Inc. · 2012
- Dual variable domain immunoglobulin and uses thereof391US 7,612,181 B2Abbott Laboratories · 2009